1). Kessler CM. An introduction to factor VIII inhibitors: the detection and quantitation. Am J Med. 1991; 91:1S–5S.
Article
2). Boggio LN, Green D. Acquired hemophilia. Rev Clin Exp Hematol. 2001; 5:389–404.
Article
3). Grunewald M, Beneke H, Guthner C, Germowitz A, Brommer A, Griesshammer M. Acquired haemophilia: experiences with a standardized approach. Haemophilia. 2001; 7:164–9.
4). Shaffer LG, Phillips MD. Successful treatment of acquired hemophilia with oral immunosuppressive therapy. Ann Intern Med. 1997; 127:206–9.
Article
5). Bayer RL, Lichtman SM, Allen SL, et al. Acquired factor VIII inhibitors-successful treatment with an oral outpatient regimen. Am J Hematol. 1999; 60:70–1.
Article
6). Ali R, Ozcelik T, Ozkalemkas F, et al. Successful treatment of acquired haemophilia with prednisolone therapy. Hemophilia. 2003; 9:741–3.
Article
7). Lee JJ, Chung IJ, Park MR, et al. Acquired hemophilia successfully treated with oral immunosuppressive therapy. Korean J Intern Med. 2003; 15:135–7.
Article
8). Cho IH, Choul KJ, Park JS, et al. Use of recombinant factor VIIa in acquired hemophilia A patient with active bleeding. Korean J Thromb Hemost. 2000; 7:57–81.
9). Jung SW, Kim S, Youk CM, Park KC, Oh D, Byun JH. A case of asymptomatic acquired hemophilia. Korean J Thromb Hemost. 2001; 8:59–62.
10). Gralnick HR, Maisonneuve P, Sultan Y, Rick ME. Benefits of danazol treatment in patients with hemo-phila A (classic hemophilia). JAMA. 1985; 253:1151–3.
11). Gralnick HR, Rick ME. Danazol increases factor VIII and factor IX in classic hemophilia and Christmas disease. N Engl J Med. 1983; 308:1393–5.
Article
12). Lozner EL, Jolliffe LS, Taylor FHL. Haemorrhagic diathesis with prolonged coagulation time associated with a circulating anticoagulant. Am J Med Sci. 1940; 199:318–27.
13). Hultin MB. Acquired inhibitors in malignant and nonmalignant disease state. Am J Med. 1991; 91:9S–13S.
14). Delgado J, Jimenez-Yuste V, Hernandez-Navarro F, Villar A. Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors. Br J Haematol. 2003; 121:21–35.
Article
15). Green D. Immunosuppression of patients with acquired factor VIII inhibitors. Semin Hematol. 1994; 31:60–1.
16). Saxena R, Mishra DK, Kashyap R, Choudhry VP, Mahapatra M, Bhargava M. Acquired haemophilia-a study of ten cases. Haemophilia. 2000; 6:78–83.
17). Schreiber AD, Chien P, Tomaski A, Cines DB. Effect of danazol in immune thrombocytopenic purpura. N Engl J Med. 1987; 316:503–8.
Article
18). Ahn YS, Harrington WJ, Simon SR, Mylvaganam R, Pall LM, So AG. Danazol for the treatment of idiopathic thrombocytopenic purpura. N Engl J Med. 1983; 308:1396–9.
Article
19). Mylvaganam R, Ahn YS, Harrington WJ, Kim CI. Immune modulation by danazol in autoimmune thrombocytopenia. Clin Immunol Immunopathol. 1987; 42:281–7.
Article